P2.11-01 A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer

Aberrant MET pathway is associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Recently, several selective MET inhibitors have shown promising antitumor effects in NSCLC with MET exon 14 skipping mutation and MET amplification. We evaluated the efficacy and safety of tepotinib in patients with advanced solid cancers harboring these MET alterations, and report the results of NSCLC patients here.